AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4% – Should You Sell?

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price dropped 5.4% on Monday . The stock traded as low as $20.51 and last traded at $20.51. Approximately 10,002 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 342,041 shares. The stock had previously closed at $21.68.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ANAB shares. Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Wedbush reissued an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research report on Thursday, September 26th. Guggenheim boosted their target price on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. JPMorgan Chase & Co. raised their price target on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a report on Thursday. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $55.73.

AnaptysBio Trading Down 7.1 %

The company’s fifty day moving average is $34.28 and its 200-day moving average is $29.94. The firm has a market capitalization of $552.71 million, a P/E ratio of -3.15 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The firm had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. On average, equities research analysts anticipate that AnaptysBio, Inc. will post -6.84 EPS for the current year.

Insider Buying and Selling

In other AnaptysBio news, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of AnaptysBio stock in a transaction dated Wednesday, August 14th. The stock was bought at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now owns 7,794,996 shares of the company’s stock, valued at $284,517,354. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were purchased at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the purchase, the insider now directly owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 22,440 shares of company stock valued at $892,936. Insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Several institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC bought a new position in shares of AnaptysBio during the 1st quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in AnaptysBio during the first quarter valued at approximately $265,000. Susquehanna Fundamental Investments LLC acquired a new stake in AnaptysBio during the first quarter valued at approximately $1,221,000. Acadian Asset Management LLC bought a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $420,000. Finally, Platinum Investment Management Ltd. acquired a new position in shares of AnaptysBio in the 1st quarter worth approximately $1,490,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.